Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tozadenant Safety Study in PD
NCT03051607Phase 3Terminated
- Sponsor
- Biotie Therapies
- Start
- Apr 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of tozadenant in Parkinson's disease (PD), sponsored by Biotie Therapies. Started Apr 2017; status: terminated.
02
Drugs
tozadenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03051607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051607.